These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 25877940)
1. Bortezomib-containing regimens are effective in multiple myeloma--results of a non-interventional phase IV study. Knauf W; Tapprich C; Schlag R; Schütz S; Alkemper B; Gaede B; Reschke D; Schmits R; Schwarzer A Oncol Res Treat; 2015; 38(4):167-73. PubMed ID: 25877940 [TBL] [Abstract][Full Text] [Related]
2. An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. Spicka I; Mateos MV; Redman K; Dimopoulos MA; Richardson PG Immunotherapy; 2011 Sep; 3(9):1033-40. PubMed ID: 21913826 [TBL] [Abstract][Full Text] [Related]
3. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713 [TBL] [Abstract][Full Text] [Related]
4. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561 [TBL] [Abstract][Full Text] [Related]
5. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens. Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740 [TBL] [Abstract][Full Text] [Related]
7. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218 [TBL] [Abstract][Full Text] [Related]
8. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914 [TBL] [Abstract][Full Text] [Related]
9. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
10. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
11. A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Kim MK; Kim K; Min CK; Kwak JY; Bae SB; Yoon SS; Lee JJ; Kim KH; Nam SH; Mun YC; Kim HJ; Bae SH; Shin HJ; Lee JH; Park JS; Jeong SH; Lee MH; Kim YS; Lee HS; Park KW; Lee WS; Lee SM; Lee JO; Hyun MS; Jo DY; Lim SN; Lee JH; Cho DY; Do YR; Kim JA; Park SK; Kim JS; Kim SJ; Kim H; Yi HG; Moon JH; Choi CW; Kim SH; Joo YD; Kim HG; Kim BS; Park MR; Song MK; Kim SY Oncotarget; 2017 Jun; 8(23):37605-37618. PubMed ID: 28402945 [TBL] [Abstract][Full Text] [Related]
12. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG; N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647 [TBL] [Abstract][Full Text] [Related]
13. Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. Lee SR; Choi H; Lee BH; Kang KW; Yu ES; Kim DS; Park Y; Choi CW; Kim BS; Sung HJ Korean J Intern Med; 2019 Nov; 34(6):1333-1346. PubMed ID: 30360024 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M; Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205 [TBL] [Abstract][Full Text] [Related]
15. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641 [TBL] [Abstract][Full Text] [Related]
17. Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study. Petrucci MT; Levi A; Bringhen S; Scotti S; Gentilini F; Russo S; Siniscalchi A; Larocca A; Grammatico S; Boccadoro M; Foà R; Palumbo A Cancer; 2013 Mar; 119(5):971-7. PubMed ID: 23096113 [TBL] [Abstract][Full Text] [Related]
18. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009 [TBL] [Abstract][Full Text] [Related]
19. [Induction treatment with bortezomib-cyclophosphamide-dexamethasone (CyBorD) for newly diagnosed transplant-eligible patients with multiple myeloma]. Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K Rinsho Ketsueki; 2015 Aug; 56(8):1069-75. PubMed ID: 26345569 [TBL] [Abstract][Full Text] [Related]
20. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). Tessenow H; Holzvogt M; Holzvogt B; Andrea M; Heyn S; Schliwa T; Schwarz M; Zehrfeld T; Becker C; Pfrepper C; Franke GN; Krahl R; Jentzsch M; Leiblein S; Schwind S; Bill M; Vucinic V; Lange T; Niederwieser D; Pönisch W J Cancer Res Clin Oncol; 2017 Oct; 143(10):2049-2058. PubMed ID: 28534173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]